Back to Newsroom

Axovant Sciences Announces Appointment of Dr. David Hung as Chief Executive Officer and Expansion of Board of Directors

BASEL, Switzerland, April 10, 2017 /PRNewswire/ — Axovant Sciences (NYSE: AXON), a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced that David Hung, MD, has been named Chief Executive Officer of Axovant Sciences, effective April 7, 2017. Dr. Hung, who also joined Axovant’s Board of Directors, succeeds founding Chief Executive Officer Vivek Ramaswamy. Mr. Ramaswamy will continue to serve on Axovant’s Board of Directors and will lead parent company and majority owner Roivant Sciences as its full-time Chief Executive Officer.

Click here to read the full release